PL2968427T3 - Koniugat do indukowania przeciwciał ukierunkowanych na polisacharydy ściany komórkowej grzybów - Google Patents

Koniugat do indukowania przeciwciał ukierunkowanych na polisacharydy ściany komórkowej grzybów

Info

Publication number
PL2968427T3
PL2968427T3 PL14774732.3T PL14774732T PL2968427T3 PL 2968427 T3 PL2968427 T3 PL 2968427T3 PL 14774732 T PL14774732 T PL 14774732T PL 2968427 T3 PL2968427 T3 PL 2968427T3
Authority
PL
Poland
Prior art keywords
conjugate
cell wall
fungal cell
antibodies targeting
inducing antibodies
Prior art date
Application number
PL14774732.3T
Other languages
English (en)
Polish (pl)
Inventor
Francis Michon
Frank Comer
Kuishu REN
Samuel J. Wohlstadter
Original Assignee
Wellstat Vaccines, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Vaccines, Llc filed Critical Wellstat Vaccines, Llc
Publication of PL2968427T3 publication Critical patent/PL2968427T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
PL14774732.3T 2013-03-12 2014-03-06 Koniugat do indukowania przeciwciał ukierunkowanych na polisacharydy ściany komórkowej grzybów PL2968427T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361777631P 2013-03-12 2013-03-12
PCT/US2014/021128 WO2014158963A1 (en) 2013-03-12 2014-03-06 Antibodies targeted to fungal cell wall polysaccharides

Publications (1)

Publication Number Publication Date
PL2968427T3 true PL2968427T3 (pl) 2023-02-27

Family

ID=51625093

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14774732.3T PL2968427T3 (pl) 2013-03-12 2014-03-06 Koniugat do indukowania przeciwciał ukierunkowanych na polisacharydy ściany komórkowej grzybów

Country Status (10)

Country Link
US (6) US20160017062A1 (https=)
EP (1) EP2968427B1 (https=)
JP (2) JP6434958B2 (https=)
CN (1) CN105188725B (https=)
AU (1) AU2014241492A1 (https=)
DK (1) DK2968427T3 (https=)
ES (1) ES2936811T3 (https=)
FI (1) FI2968427T3 (https=)
PL (1) PL2968427T3 (https=)
WO (1) WO2014158963A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014158963A1 (en) 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法
CN111707815A (zh) * 2019-12-31 2020-09-25 安徽中医药大学 一种通过白色念珠菌细胞壁重构来评价中药单体抗真菌作用的方法
CN113274489B (zh) * 2021-04-30 2023-08-29 山东省药学科学院 一种预防真菌感染的几丁质寡糖疫苗及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62138496A (ja) 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
JP2871822B2 (ja) * 1989-08-29 1999-03-17 玉造株式会社 末端に２，５―アンヒドロマンニトール基または２，５―アンヒドロマンノース基を有するキチン・キトサンオリゴマーおよびその製造方法
JP2868635B2 (ja) * 1991-02-25 1999-03-10 玉造株式会社 キチン・キトサンオリゴマーの精製方法
JP2786389B2 (ja) * 1993-05-18 1998-08-13 玉造株式会社 腫瘍免疫治療剤
US5705634A (en) 1995-03-02 1998-01-06 Perimmune Holdings, Inc. High yield preparation of dimeric to decameric chitin oligomers
US6284884B1 (en) * 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
DK1448607T3 (da) * 2001-11-15 2011-04-26 Piramal Healthcare Canada Ltd Sammensætning og fremgangsmåde til homogen modificering eller krydsbinding af chitosan under neutrale betingelser
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
EP1863536A4 (en) * 2005-03-14 2011-07-20 Univ Alberta VACCINE BASED ON SYNTHETIC OLIGOSACCHARIDES AGAINST CANDIDA ALBICANS
AU2006257177A1 (en) 2005-06-14 2006-12-21 Genis Ehf. Compositions of partially deacetylated chitin derivatives
KR100793756B1 (ko) * 2006-08-07 2008-01-10 엘지전자 주식회사 녹화 목록 표시 방법 및 그 장치
US20080311595A1 (en) 2007-06-18 2008-12-18 Inger Mattsby-Baltzer Rapid fungal detection assay and product
GB2460965B (en) * 2008-03-13 2010-05-19 Academia Sinica Fibrillar albumin and uses thereof
EP2123261A1 (en) 2008-05-20 2009-11-25 Stallergenes S.A. Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
US20110274713A1 (en) * 2008-08-05 2011-11-10 The University Of Queensland Antigen-presenting scaffolds
BRPI0918806B1 (pt) 2008-09-05 2019-02-05 Ceva Sante Animale Sa Composição de vacina compreendendo quitosana e antígeno do vírus de doença de newcastle (nvd) adaptada à administração ocular em ave, uso de quitosana e de nvd paraaumentar resposta imune em ave, bem como kit de vacinação de aves
KR101664510B1 (ko) 2008-10-23 2016-10-10 더루우브리졸코오포레이션 금속 카르복실레이트를 함유하는 윤활 조성물
JP5617127B2 (ja) * 2009-05-08 2014-11-05 大石　哲也 新規グアナミン化合物、その誘導体及びそれらの製造方法
JP5781542B2 (ja) * 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
JP2012241084A (ja) * 2011-05-18 2012-12-10 Nippon Terupen Kagaku Kk バインダー樹脂用溶剤
WO2014158963A1 (en) * 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides

Also Published As

Publication number Publication date
CN105188725B (zh) 2020-08-21
DK2968427T3 (da) 2023-01-30
US10752704B2 (en) 2020-08-25
US20190169315A1 (en) 2019-06-06
AU2014241492A1 (en) 2015-09-17
US10988552B2 (en) 2021-04-27
US10519253B2 (en) 2019-12-31
JP2016513747A (ja) 2016-05-16
US20200339707A1 (en) 2020-10-29
HK1220360A1 (en) 2017-05-05
US20200062866A1 (en) 2020-02-27
US20160017062A1 (en) 2016-01-21
US20180251573A1 (en) 2018-09-06
JP2018172696A (ja) 2018-11-08
FI2968427T3 (fi) 2023-03-01
US20210301037A1 (en) 2021-09-30
WO2014158963A1 (en) 2014-10-02
JP6434958B2 (ja) 2018-12-05
EP2968427A4 (en) 2016-08-31
EP2968427B1 (en) 2022-10-26
CN105188725A (zh) 2015-12-23
EP2968427A1 (en) 2016-01-20
ES2936811T3 (es) 2023-03-22
US10259888B2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
IL244816A0 (en) Protein-polymer-drug conjugates
IL245009A0 (en) Attach a drug from a protein and a polymer
ZA201505656B (en) Antibody drug conjugates
ZA201502267B (en) Pyrrolobenzodiazepine-anti-her2 antibody conjugates
LT2906253T (lt) Pirolobenzodiazepino-anti-psma antikūno konjugatas
LT2906251T (lt) Pirolobenzodiazepino-anti-cd22 antikūno konjugatai
HUE049446T2 (hu) Anti-FCRH5 antitestek
SG11201605260VA (en) Var2csa-drug conjugates
ZA201508487B (en) Antibody drug conjugates
IL244043A0 (en) Antibodies
EP3059225A4 (en) Novel alkylene derivative
IL240920A0 (en) Cyclosporine a-steroid conjugates
GB201314655D0 (en) Hydrophobic bank
GB201315486D0 (en) Antibodies
IL245488B (en) Anti- ccl17 antibodies
GB201312226D0 (en) Improved antibodies
ZA201507251B (en) Antibodies targeting m-csf
PL2968427T3 (pl) Koniugat do indukowania przeciwciał ukierunkowanych na polisacharydy ściany komórkowej grzybów
GB201307275D0 (en) Drivetrain Connections
GB201316666D0 (en) Targeting molecule
PL2978847T3 (pl) Rybozymy typu hammerhead skierowane przeciw mir-21
HK1230630A1 (en) Var2csa-drug conjugates
GB201313754D0 (en) Transaction pouch
GB201318283D0 (en) Antibodies